OmniSom Solutions

39 million Americans suffer from sleep apnea (SA), a serious medical condition that causes people to periodically stop breathing during sleep. Established medical research has conclusively linked SA to many downstream clinical diseases such as heart disease, stroke, and cognitive atrophy. Economic analysts have estimated undiagnosed and untreated SA has an annual cost of $45–80 billion in medical costs and up to $165 billion in total downstream economic costs in the United States. Despite these serious consequences, approximately 2 out of 3 Americans with SA remain undiagnosed. SA diagnosis requires an overnight sleep study in a fully equipped and staffed sleep center. These studies comprehensively diagnose SA by monitoring up to 10 modes of physiologic data. However, this is not only expensive and uncomfortable for patients, but current sleep clinic infrastructure is unable to meet high patient demand. As a result, 26 million Americans suffering with SA remain undiagnosed.

To overcome the diagnostic bottleneck imposed by limited clinic test infrastructure, at-home sleep monitors have been introduced that allow patients to be screened from their own bedrooms. However, no home system exists that can be self-applied by patients to record all 10 necessary physiologic signals needed for a comprehensive diagnosis. As a result, home monitors have gained limited clinical adoption and represent only 2.5%. Our team is developing The Lyra, the first sleep apnea diagnosis system that effectively transitions sleep apnea diagnosis to the home setting. The Lyra integrates traditional sleep diagnostic technology and novel dry electrodes into comfortable, sleep-friendly form factors, a headset and chest strap, which record a complete dataset equivalent to an in-clinic sleep study.